Vinorelbine and Cisplatin in Advanced Squamous Cell Carcinoma of the Cervix: The South African Experience

Background: This phase II trial was performed to assess the activity and safety of the cisplatin and vinorelbine combination in patients with advanced cervical carcinoma. Patients and Methods: Forty-two patients with advanced cervical cancer were included in the study to receive vinorelbine at 30 mg...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2005-05, Vol.25 (3C), p.2489-2492
Main Authors: GOEDHALS, Louis, FALKSON, Geoffrey, SMITH, Brenda Lynn, FALKSON, Carla Isadora, GASMI, Jamal, LATEGAN, Andries, BURILLON, Jean-Philippe, HIS, Patricia
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - pathology
Cisplatin - administration & dosage
Cisplatin - adverse effects
Drug Administration Schedule
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Medical sciences
Middle Aged
Neoplasm Staging
Tumors
Uterine Cervical Neoplasms - drug therapy
Uterine Cervical Neoplasms - pathology
Vinblastine - administration & dosage
Vinblastine - adverse effects
Vinblastine - analogs & derivatives
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: This phase II trial was performed to assess the activity and safety of the cisplatin and vinorelbine combination in patients with advanced cervical carcinoma. Patients and Methods: Forty-two patients with advanced cervical cancer were included in the study to receive vinorelbine at 30 mg/m 2 on d 1 and d 8 and cisplatin 100 mg/m 2 on day 1 every 4 weeks. Results: Thirty-seven patients were evaluable for response and 40 patients for tolerance. Twenty-four patients (64.8%) achieved objective responses. The median duration of response was 17.5 months (range 2.5-57 months), median time to progression was 13.2 months (range 0.4-57 months) and median survival was 20.6 months (range 0.4-55 months). This regimen was well-tolerated; no WHO grade 4 neutropenia was observed, grade 3 nausea and vomiting occured in 50% of patients and grade 2 peripheral neuropathy in 5% of patients. Conclusion: Vinorelbine-cisplatin is an active and well-tolerated regimen in advanced cervical carcinoma.
ISSN:0250-7005
1791-7530